Skip Navigation LinksHome > August 2013 - Volume 35 - Issue 6 > Dramatic Response to Cisplatin Window Therapy in a Boy With...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31829d452c
Clinical and Laboratory Observations

Dramatic Response to Cisplatin Window Therapy in a Boy With Advanced Metastatic Ewing Sarcoma

Trizzino, Antonino MD*; Ziino, Ottavio MD*; Parafioriti, Antonina MD; Podda, Marta MD; Tropia, Serena MD*; Luksch, Roberto MD; D’Angelo, Paolo MD*

Collapse Box

Abstract

Ewing sarcoma (ES) is the second most common type of primary bone malignancy, and retains a high propensity to metastasize; the prognosis of patients with disseminated disease is very poor, with an event-free survival rate of <20%. Current multimodality treatment for ES consists of combined chemotherapy before and concurrent with surgery and local radiotherapy for the involved bone. Cisplatin is one of the most widely used drugs for the treatment of bone tumors in children, but is not currently used in ES. We describe a child with multifocal ES, treated with a phase II trial including a single-drug window therapy, which displayed a dramatic response to 2 courses of cisplatin and had a favorable outcome.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.